Evidence map›Paper›PMID 39580494›Full record

ArticleScientific reports2024

Effect of therapeutic erythrocytapheresis on outcomes and renal benefit in patients with high-altitude polycythemia: a real-world study.

Yan Ouyang, Yinyin Zhang, Huan Li, Luo Bu Zhuo Ma, Ci Ren De Ji, Chunyan Qiao, Ba Dun, Xiaodong Gao, Jun Zhu, Pengpeng Xu and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. High-altitude polycythemia: State-of-the-art review.Therapeutic advances in hematology · 2026
    Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Yan Ouyang *Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Ruijin Hospital, National Research Center for Translational Medicine at Shanghai, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yinyin Zhang *Department of Hematology, Shigatse People's Hospital, Shigatse, Tibet Autonomous Region, China.
Huan Li *Department of Hematology, Shigatse People's Hospital, Shigatse, Tibet Autonomous Region, China.
Luo Bu Zhuo MaDepartment of Hematology, Shigatse People's Hospital, Shigatse, Tibet Autonomous Region, China.
Ci Ren De JiDepartment of Hematology, Shigatse People's Hospital, Shigatse, Tibet Autonomous Region, China.
Chunyan QiaoDepartment of Hematology, Shigatse People's Hospital, Shigatse, Tibet Autonomous Region, China.
Ba DunDepartment of General Practice, Shigatse People's Hospital, Shigatse, Tibet Autonomous Region, China.
Xiaodong GaoShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Ruijin Hospital, National Research Center for Translational Medicine at Shanghai, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jun ZhuShanghai Zhaxin Traditional Chinese & Western Medicine Hospital, Shanghai, China.
Pengpeng XuShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Ruijin Hospital, National Research Center for Translational Medicine at Shanghai, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yu ZhengShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Ruijin Hospital, National Research Center for Translational Medicine at Shanghai, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xiaoyang LiShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Ruijin Hospital, National Research Center for Translational Medicine at Shanghai, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jianhua YouShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Ruijin Hospital, National Research Center for Translational Medicine at Shanghai, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Chuanhe JiangShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Ruijin Hospital, National Research Center for Translational Medicine at Shanghai, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Fei YueDepartment of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Junmin LiShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Ruijin Hospital, National Research Center for Translational Medicine at Shanghai, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Pu Bu Wang DuiDepartment of Hematology, Shigatse People's Hospital, Shigatse, Tibet Autonomous Region, China. Pw13908922332@163.com.
Kai XueShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Ruijin Hospital, National Research Center for Translational Medicine at Shanghai, Shanghai Jiao Tong University School of Medicine, Shanghai, China. xuekaishanghai@126.com.
Kai QingShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Ruijin Hospital, National Research Center for Translational Medicine at Shanghai, Shanghai Jiao Tong University School of Medicine, Shanghai, China. qk12217@rjh.com.cn.

Funding

National Natural Science Foundation of China 82270739Natural Science Foundation of Shigatse RKZ2024ZR-003(Z)Natural Science Foundation of Tibet Autonomous Region XZ2019ZR-ZY50(Z)Natural Science Foundation of Tibet Autonomous Region XZ2024ZR-ZY048(Z)Shanghai Jiao Tong University "Jiao tong Star" Plan Medical Engineering Cross Research Key Project YG2019QNA37Shanghai Municipal Health Commission General Program 202040040Shanghai "Rising Stars of Medical Talent" Youth Development Program-Youth Medical Talents-Specialty, General Practice Programs SHWSRS(2023)_062Shanghai Shenkang Hospital Development Center Second Round of the 'Three-Year Action Plan for Enhancing Clinical Skills and Clinical Innovation in Municipal Hospitals (2023-2025)' Simulated RCT Study Project SHDC2024CRI006
6 · The paper itself

Abstract

Kidney injury from high-altitude polycythemia (HAPC) is common, yet few studies have explored effective treatments. This research assessed the renal benefits of therapeutic erythrocytapheresis (TE) in HAPC patients, analyzing the efficacy of single versus multiple treatments. From 2017 to 2023, 631 patients undergoing TE were included. Findings showed notable improvements in hemoglobin levels (median: 228.00 vs. 169.00 g/L, p < 0.001), estimated glomerular filtration rate (eGFR) (median: 100.24 vs. 105.92 ml/min/1.73 m

Indexed as

AltitudeGlomerular Filtration RatePolycythemiaAdultAltitude SicknessCytapheresisErythrocytesErythrocyte TransfusionFemaleHemoglobinsHumansKidneyMaleMiddle AgedRetrospective StudiesTreatment OutcomeHemoglobinsHigh-altitude polycythemiaMultiple treatmentsRenal benefitsTherapeutic erythrocytapheresis

Identifiers

PMID39580494
PMCPMC11585537

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.